Sign in to view content

Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD

Carl C. Awh, MD, FASRS

Video
Published 2021

Related

Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more